| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794822 | Ophthalmology Retina | 2017 | 8 Pages |
Abstract
Physician-reported outcomes on ocriplasmin use confirmed VMA release in 45% and closure of MH in 40% of eyes without PPVx. Visual acuity decreased in approximately 20% of eyes. Adverse events were not infrequent and suggest caution when considering ocriplasmin use.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Jennifer I. MD, Adam R. MS, Lloyd Paul MD, PhD, Usha MD, Christina J. MD, Lawrence J. MD, Richard F. MD, Daniel B. MD,